Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3928768 | 0.78 | CALM1 (0.55) | ALDH1A1CALM1CYP11B1CYP11B2 | |
| SCHEMBL29442828 | 0.78 | NFE2L2 (0.45) | L3MBTL1GAAMAPTKDM4EMAOB | |
| SCHEMBL21384192 | 0.78 | NFE2L2 (0.45) | L3MBTL1GAAMAPTKDM4EMAOB | |
| SCHEMBL4712682 | 0.77 | GRM4 (0.48) | L3MBTL1GAAMAPTKDM4EALDH1A1 | |
| SCHEMBL17851265 | 0.77 | ALDH1A1 (0.56) | MAPTALDH1A1KMT2A | |
| SCHEMBL9430612 | 0.76 | CALM1 (0.46) | MAPTALDH1A1CALM1CYP11B1CYP11B2 | |
| SCHEMBL7992427 | 0.76 | GAA (0.60) | L3MBTL1GAAMAPTKDM4EALDH1A1 | |
| SCHEMBL8135078 | 0.76 | L3MBTL1 (0.51) | L3MBTL1GAAMAPTKDM4EALDH1A1 | |
| SCHEMBL1191064 | 0.75 | GABRP (0.53) | CALM1CYP11B1CYP11B2 | |
| SCHEMBL1601726 | 0.75 | CALM1 (0.50) | ALDH1A1CALM1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PROGENTOS THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| EP-4430047-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Progentos Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| CN-118475580-A | Platelet-derived growth factor receptor (PDGFR) alpha inhibitors and uses thereof | 普罗根托斯治疗公司 | 2024-08-09 | — | — | CN | disclosed |
| WO-2023081923-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Frequency Therapeutics, Inc. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081923-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Frequency Therapeutics, Inc. (US) | 2023-05-11 | — | — | WO | disclosed |
| EP-0546418-B1 | Process for the preparation of 5-substituted 2-chloropyridines | BAYER AG (DE) | 2001-10-17 | — | — | EP | disclosed |
| US-5304651-A | Chlorination and cyclization of N-substituted acetamides | BAYER AKTIENGESELLSCHAFT (DE) | 1994-04-19 | — | — | US | disclosed |
| EP-0546418-A1 | Process for the preparation of 5-substituted 2-chloropyridines | BAYER AG (DE) | 1993-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PDGFRB, PDGFRA, PDGFA | L3MBTL1 4587/4885GAA 1256/4885MAPT 2829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.